Phaseline

Targets › INH

INH: drug programs, companies and trials

2 programs from 2 companies in 5 trials: 4 Phase 4, 1 Phase 1; Infectious disease; next expected readout Aug 2029.

Open in Phaseline: the race on INH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Affiliated Hospital of Nantong UniversityIsoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
INH, RIF, RPTPhase 4Latent Tuberculosis Infection (LTBI)Aug 2029
The Aurum Institute NPCRifapentine
Bacterial DNA-directed RNA polymerase inhibitor
RIPA, INH, UNKNOWNPhase 4HIV Seropositivity–

Conditions

HIV Seropositivity (3) Latent Tuberculosis Infection (LTBI) (2)

Modalities

small molecule (2)

Companies

The Aurum Institute NPC (1) Affiliated Hospital of Nantong University (1)

Related targets

RIPA (1) UNKNOWN (1) RIF (1) RPT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.